Patent US4639468A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4639468A Expired / Lapsed US ⏱️ 0.0 years remaining

Derivatives of glycinamide, their preparation and their use

Assignee: Continental Pharma Inc
•
Filing: 1985-08-23
•
Granted: 1987-01-27
•
Expires: 2005-08-23
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A glycinamide derivative of the general formula I: <IMAGE> (I) wherein: R is a linear or ramified alkyl group C5-C18, a linear or ramified alkenyl group C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17 or C18, a linear or ramified alkynyl group C4-C10, a linear or ramified acyl group C4-C18, a linear or ramified alkyl group C1-C10, substituted by a phenoxy group, by a hydroxy radical, by an acetoxy radical, by a carboxy radical, by a linear or ramified alkoxycarbonyl group C1-C4, by a carbonyl radical, by a carboxaldehyde group, by an acetal or cetal group, by one or more phenyl groups, by one or more phenyl groups substituted by a halogen atom such as fluorine, chlorine or bromine, R1 represents hydrogen, a linear or ramified alkyl group C1, C2, C3, C4, C5, C6, C7, C8, C9 or C10, a linear or ramified acyl group C1-C6, a benzoyl group, a linear or ramified alkoxycarbonyl group C1, C2, C3, C4, C5, C6, C7 or C8, a carboxamidomethyl group, R2 represents hydrogen, a linear or ramified alkyl C1, C2, C3, a phenyl group, R3 represents hydrogen, a linear or ramified alkyl group C1, C2, C3, C4, C5, C6, C7 or C8, a phenyl group, optionally substituted by a halogen atom, such as fluorine, chlorine or bromine, R4 represents hydrogen, a linear or ramified alkyl group C1, C2, C3, C4, C5, C6, C7 or C8 as well as salts of these derivatives with non toxic and pharmaceutically usable acids.

Inventors

  • 👤 Romeo Roncucci
  • 👤 Claude L. Gillet
  • 👤 Alexis H. Cordi
  • 👤 Mark A. Martens
  • 👤 Joseph L. Roba
  • 👤 Paul J. Niebes
  • 👤 Georges E. Lambelin
  • 👤 William R. Van Dorsser

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-09 05:55
CPC Classifications
C; C07; C07C; C07C255/00; C07C271/00; C07C271/06; C07C271/08; C07C271/10; C07C271/22

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 88 words
A pharmaceutical composition containing as the active ingredient an effective amount, for the treatment of epilepsy, dyskinesiae, memory troubles and psychic troubles, of a glycinamide derivative of the formula: ##STR74## wherein: R is a linear pentyl group, or a linear or branched C 2 -C 5 alkyl group substituted by at least one phenyl group or at least one halo-substituted phenyl group, R 1 is hydrogen, and R 2 is hydrogen, or the non-toxic, pharmaceutically acceptable acid addition salt thereof together with a pharmaceutically acceptable carrier or diluent.
Claim 2
Dependent Claim 88 words
A pharmaceutical composition containing as the active ingredient an effective amount, for the treatment of epilepsy, dyskinesiae, memory troubles and psychic troubles, of a glycinamide derivative of the formula: ##STR74## wherein: R is a linear pentyl group, or a linear or branched C 2 -C 5 alkyl group substituted by at least one phenyl group or at least one halo-substituted phenyl group, R 1 is hydrogen, and R 2 is hydrogen, or the non-toxic, pharmaceutically acceptable acid addition salt thereof together with a pharmaceutically acceptable carrier or diluent.
Claim 3
Dependent Claim 20 words
The pharmaceutical composition according to claim 1 wherein the halo phenyl is substituted with a fluorine, bromine or chlorine atom.
Claim 4
Dependent Claim 21 words
The pharmaceutical composition according to claim 1 in a unit dose containing from 10 to 300 mg. of said glycinamide derivative.
Claim 5
Dependent Claim 41 words
A pharmaceutical composition containing as the active ingredient an effective amount of 2-n-pentylaminoacetamide, for the treatment of epilepsy, dyskinesiae, memory troubles and psychic troubles, or the non-toxic, pharmaceutically acceptable acid addition salt thereof together with a pharmaceutically acceptable carrier or diluent.
Claim 6
Dependent Claim 41 words
A pharmaceutical composition containing as the active ingredient an effective amount of 2-n-pentylaminoacetamide, for the treatment of epilepsy, dyskinesiae, memory troubles and psychic troubles, or the non-toxic, pharmaceutically acceptable acid addition salt thereof together with a pharmaceutically acceptable carrier or diluent.
Claim 7
Dependent Claim 24 words
A pharmaceutical composition in unit dose form for treating tonic convulsions containing from 10 to 300 mg. of the glycinamide derivative of claim 4.

References Cited (Backward Citations)

US2368208A Cited
US2781385A Cited
FR2637M Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1990-01-26 1990-07-28 1991-01-27 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1994-01-26 1994-07-28 1995-01-27 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1998-01-26 1998-07-28 1999-01-27 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag